In our study, we developed an ultrasomic model, a clinical model, and a combined model derived from pre-treatment ultrasound images to noninvasively predict the objective response to TKI combined with anti-PD-1 therapy in unresectable HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.